Alivus Life Sciences Ltd logo

Alivus Life Sciences Ltd

ALIVUS NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹17,311 Cr
Volatility
Moderate
P/E Ratio
28.4
EBITDA
₹858 Cr
Return on Equity
16.94%
Debt to Equity
0.02
Book Value
₹271.41
EPS
₹36.48
52W High
₹1,493.8
52W Low
₹819

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Alivus Life Sciences Ltd insights

55 extracted metrics + investor summaries across FY18–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 27.4%

Weaknesses

2
  • The company has delivered a poor sales growth of 6.24% over past five years.
  • Company has high debtors of 153 days.

Growth Rate

Revenue Growth
7.88% higher than 3Y
Net Income Growth
16.25% higher than 3Y
Cash Flow Change
44.41% higher than 3Y
ROE
-1.74% lower than 3Y
ROCE
-2.42% higher than 3Y
EBITDA Margin (Avg.)
10.84% higher than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 5d ago
AI opinion · based on fundamentals
Risk medium

Alivus Life Sciences Ltd is a small-cap healthcare company with a market cap of ₹17,192 Cr, trading at a PE of 28.9x and a PB of 5.23x. The company is nearly debt-free with a healthy 5-year ROE averaging around 21%, but revenue growth has been sluggish at a 5-year CAGR of just 6%, while debtor days stand elevated at 153 days.

Bull Case 8
  • The company is almost debt-free, providing financial flexibility and lower interest burden in a rising rate environment
  • 5-year average ROE of 21% indicates efficient capital allocation and strong profitability relative to equity deployed
  • Last year ROE of 18% remains healthy and well above the cost of equity for most Indian companies
  • Stock price CAGR of 53% over the past 1 year reflects strong market re-rating and investor interest
  • Consistent dividend payout ratio of 27.4% signals management confidence in cash flow sustainability and shareholder-friendly capital return policy
  • TTM profit growth of 25% significantly outpaces TTM sales growth of 8%, suggesting margin expansion and improving operating leverage
  • 3-year stock CAGR of 31% indicates sustained wealth creation over a medium-term horizon
  • Dividend yield of 0.35% provides a modest income component, uncommon among small-cap healthcare peers
Bear Case 8
  • 5-year compounded sales growth of just 6% is poor for a healthcare company, lagging the broader pharma sector's typical double-digit growth
  • Debtor days of 153 days are significantly elevated, tying up working capital and raising collection risk
  • PE of 28.9x is demanding given the modest 6% revenue CAGR over 5 years, implying stretched valuations relative to growth
  • 3-year compounded profit growth of only 6% suggests the recent TTM profit spike of 25% may not be sustainable
  • Price-to-book ratio of 5.23x is rich for a company with single-digit topline growth, leaving limited margin of safety
  • TTM sales growth has decelerated to 8% from the already low 5-year CAGR of 6%, showing no clear acceleration trend
  • Absence of reported ROCE and EPS data limits visibility into overall capital efficiency and per-share earnings power
  • 52-week high and low data are unavailable, making it difficult to assess where the stock trades relative to its recent range

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 10h ago
Positives 4
  • PAT up 16%, record EBITDA margin Aug 11

    FY26 net profit rose 16% YoY to ₹5,645 million on revenue of ₹25,518 million (up 7%), with EBITDA margin hitting a record 33.6%, driven by non-GPL business and CDMO recovery.

  • ₹5 dividend approved at AGM Sep 8

    All four resolutions passed at the 15th AGM on Sep 8, including a final dividend of ₹5 per share and director reappointment with overwhelming shareholder support.

  • 76% stake in IQGenX Pharma Aug 18

    Board approved acquisition of 76% in IQGenX Pharma for ₹9.12 crore to strengthen API and CDMO capabilities. IQGenX reported FY26 turnover of ₹348 lakh; deal closure targeted by Dec 6, 2026.

  • FY26 BRSR with BSI assurance Aug 11

    Submitted FY26 Business Responsibility & Sustainability Report with 54.4% export contribution and voluntary limited assurance by British Standards Institution on core ESG KPIs.

Neutral 2
  • Active investor engagement schedule Sep 5

    Multiple one-on-one investor meetings scheduled from late Aug through Sep 9 with Breakout Capital, UTI, Kotak MF, Param Capital, Mirae Asset, and Emkay Global across Mumbai in virtual and in-person formats.

  • 15th AGM agenda announced Aug 11

    AGM scheduled for Sep 8, 2026 with key agenda items including ₹5 final dividend and re-appointment of Hiren Patel as Non-Executive Director.

TL;DR: Alivus Life Sciences is in solid shape — FY26 delivered record EBITDA margins of 33.6% and 16% PAT growth, while the ₹5 dividend signals confidence in cash flows. The IQGenX acquisition adds API/CDMO depth, and heavy institutional investor engagement suggests growing market interest. No material headwinds are visible in recent news; the key watch item is execution on the IQGenX integration and sustaining margin expansion into FY27.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
578
595
573
537
589
507
642
650
602
588
673
689
640
Expenses
385
428
400
395
429
373
452
451
430
409
442
475
429
Operating Profit
193
167
173
141
159
134
190
198
172
179
231
215
212
OPM %
33%
28%
30%
26%
27%
27%
30%
31%
29%
30%
34%
31%
33%
Other Income
2
5
2
3
5
9
10
10
9
15
-12
23
22
Interest
0
0
0
0
0
0
0
1
1
1
1
1
1
Depreciation
13
13
13
15
14
15
15
16
17
18
20
20
21
PBT
182
159
161
130
150
127
185
191
163
174
198
216
212
Tax %
26%
25%
26%
24%
26%
25%
26%
26%
25%
25%
24%
25%
25%
Net Profit
135
119
119
98
111
95
137
142
122
130
150
163
160
EPS in Rs
11.05
9.69
9.69
7.99
9.1
7.78
11.18
11.58
9.91
10.6
12.25
13.25
13.04
Figures in ₹ Crores

Profit & Loss

  Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
0
886
1,537
1,885
2,123
2,161
2,283
2,387
2,552
2,590
Expenses
0
638
1,064
1,294
1,506
1,518
1,608
1,702
1,754
1,754
Operating Profit
0
248
473
592
617
643
675
684
798
837
OPM %
-4%
28%
31%
31%
29%
30%
30%
29%
31%
32%
Other Income
0
0
11
0
14
28
11
33
34
48
Interest
0
1
34
88
28
1
2
2
5
5
Depreciation
0
19
29
33
38
42
53
61
75
79
PBT
0
228
421
471
565
629
631
654
751
801
Tax %
4200%
14%
26%
25%
26%
26%
25%
26%
25%
—
Net Profit
0
196
313
352
419
467
471
486
564
603
EPS in Rs
-430
998
1,597
359
34.17
38.11
38.43
39.63
45.99
49.14
Div. Payout %
0%
0%
0%
0%
61%
110%
59%
13%
11%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.01
2
2
2
25
25
25
25
25
Reserves
-1
86
400
751
2,030
2,114
2,308
2,793
3,308
Borrowings
0
0
0
0
3
19
17
57
57
Other Liabilities
1
1,387
1,324
1,244
414
545
501
537
594
Total Liabilities
0
1,475
1,726
1,997
2,471
2,702
2,850
3,411
3,983
Fixed Assets
0
456
546
573
595
781
805
955
1,038
CWIP
0
80
11
14
92
62
106
102
284
Investments
0
0
0
0
0
0
0
478
780
Other Assets
0
939
1,169
1,410
1,784
1,860
1,939
1,877
1,881
Total Assets
0
1,475
1,726
1,997
2,471
2,702
2,850
3,411
3,983
Figures in ₹ Crores

Cash Flow

  Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
10
195
388
598
306
414
392
565
Investing
0
-9
-51
-69
-122
-147
-116
-616
-570
Financing
0
1
-137
-214
-79
-388
-279
-6
-64
Net Cash Flow
0
2
8
106
397
-228
18
-230
-69
Free Cash Flow
0
1
144
322
466
143
285
226
259
CFO/OP
4,800
14
61
84
119
71
85
81
93
Figures in ₹ Crores

Ratios

  Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
44
185
152
120
116
136
122
148
153
Inventory Days
162
441
227
214
185
224
251
237
246
Days Payable
41
201
111
92
110
158
139
137
132
Cash Conversion Cycle
165
424
268
241
190
202
235
248
267
Working Capital Days
-2,059
-186
-37
12
149
176
188
201
194
ROCE %
—
529%
186%
97%
42%
30%
28%
25%
24%

Shareholding Pattern

Others2.36%Promot.74.87%FIIs5.54%DIIs7.18%Public10.05%As ofJun 2026

Documents

Frequently Asked Questions about Alivus Life Sciences Ltd

What does Alivus Life Sciences Ltd do?
Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic ther...
Where is Alivus Life Sciences Ltd (ALIVUS) listed?
Alivus Life Sciences Ltd trades as ALIVUS on the NSE and under code 543322 on the BSE.
Which sector does Alivus Life Sciences Ltd belong to?
Alivus Life Sciences Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Alivus Life Sciences Ltd?
Alivus Life Sciences Ltd has a market capitalisation of ₹17,311 Cr, which places it in the Mid Cap band.
What is the PE ratio of Alivus Life Sciences Ltd?
Alivus Life Sciences Ltd trades at a PE ratio of 28.40, on earnings per share of ₹36.48, against a book value of ₹271.41 per share.
What is the 52-week high and low of Alivus Life Sciences Ltd?
Over the last 52 weeks Alivus Life Sciences Ltd has traded between ₹819 and ₹1,493.8.
Does Alivus Life Sciences Ltd pay dividends?
Alivus Life Sciences Ltd has a dividend yield of 0.36%.
What is the Return on Equity (ROE) of Alivus Life Sciences Ltd?
Alivus Life Sciences Ltd reported a return on equity of 16.94%. Its debt-to-equity ratio is 0.02.

Company Information

Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.

Website glenmarklifesciences.com
CEO Dr. Yasir Yusufali Rawjee Ph.D.
Employees 2,203
Listed 2021-08-06
Face Value ₹ 2
Issued Size 12,26,81,348

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ALIVUS.md for Alivus Life Sciences Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List